SCYNEXIS, Inc. (SCYX)
NASDAQ: SCYX · Real-Time Price · USD
0.6422
-0.0178 (-2.70%)
Nov 3, 2025, 1:45 PM EST - Market open
SCYNEXIS Revenue
SCYNEXIS had revenue of $1.36M in the quarter ending June 30, 2025, with 85.33% growth. This brings the company's revenue in the last twelve months to $3.26M, down -66.30% year-over-year. In the year 2024, SCYNEXIS had annual revenue of $3.75M, down -97.33%.
Revenue (ttm)
$3.26M
Revenue Growth
-66.30%
P/S Ratio
9.95
Revenue / Employee
$116,321
Employees
28
Market Cap
26.92M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.75M | -136.40M | -97.33% |
| Dec 31, 2023 | 140.14M | 135.05M | 2,652.72% |
| Dec 31, 2022 | 5.09M | -8.07M | -61.32% |
| Dec 31, 2021 | 13.16M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
SCYX News
- 19 days ago - SCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO Study - GlobeNewsWire
- 2 months ago - SCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12) - GlobeNewsWire
- 2 months ago - SCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study - GlobeNewsWire
- 8 months ago - SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 1 year ago - SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - GlobeNewsWire
- 1 year ago - SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024 - GlobeNewsWire